Predictive Markers for the Efficacy of Anti–PD-1/PD-L1 Antibodies in Lung Cancer
Open Access
- 1 March 2016
- journal article
- review article
- Published by Elsevier BV in Journal of Thoracic Oncology
- Vol. 11 (7), 976-988
- https://doi.org/10.1016/j.jtho.2016.02.015
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- Molecular Epidemiology of EGFR and KRAS Mutations in 3,026 Lung Adenocarcinomas: Higher Susceptibility of Women to Smoking-Related KRAS-Mutant CancersClinical Cancer Research, 2012
- Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals Of Oncology, 2012
- Genomic Landscape of Non-Small Cell Lung Cancer in Smokers and Never-SmokersCell, 2012
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced CancerNew England Journal of Medicine, 2012
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- The blockade of immune checkpoints in cancer immunotherapyNature Reviews Cancer, 2012
- DNA mismatch repair deficiency in sporadic colorectal cancer and Lynch syndromeHistopathology, 2009
- Tissue expression of PD-L1 mediates peripheral T cell toleranceThe Journal of Experimental Medicine, 2006
- Autoimmune Dilated Cardiomyopathy in PD-1 Receptor-Deficient MiceScience, 2001
- Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte ActivationThe Journal of Experimental Medicine, 2000